Shares of Evotec AG (NASDAQ:EVO – Get Free Report) dropped 6.7% during trading on Tuesday. The stock traded as low as $1.49 and last traded at $1.4550. 44,695 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 100,069 shares. The stock had previously closed at $1.56.
Analysts Set New Price Targets
A number of brokerages recently weighed in on EVO. HC Wainwright upped their target price on shares of Evotec from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Evotec presently has an average rating of “Hold” and a consensus target price of $3.50.
Check Out Our Latest Research Report on Evotec
Evotec Price Performance
The business has a 50 day moving average of $1.59 and a 200 day moving average of $2.42. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.19 and a current ratio of 2.32.
Institutional Inflows and Outflows
A hedge fund recently raised its position in Evotec stock. Optiver Holding B.V. lifted its holdings in Evotec AG (NASDAQ:EVO – Free Report) by 598.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the quarter. Optiver Holding B.V. owned 0.08% of Evotec worth $709,000 at the end of the most recent quarter. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
About Evotec
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.
Further Reading
- Five stocks we like better than Evotec
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
